Remdesivir improves time to recovery in Covid-19 patients, says new study

The researchers, including those from the New York University in the US, found that remdesivir was most beneficial for hospitalised patients with severe disease requiring supplemental oxygen

Remdesivir, the antiviral drug under clinical trials for treatment against novel coronavirus infection, is superior to the standard of care given to Covid-19 patients, according to a new study.

The analysis, published in the New England Journal of Medicine, is based on data from the Adaptive Covid-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in the US, news agency PTI reported.

In the randomised, controlled trial, clinicians enrolled adults hospitalised with Covid-19 who showed infection in the lower respiratory tract and suffered from moderate to severe disease.

The researchers, including those from the